Gritstone: Positive Preclinical Data in 2nd-Gen COVID Vaccine

 Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques

Potential for equivalent or more potent immune responses at lower doses with SAM compared to first-generation mRNA vaccines; strong T cell responses observed

Initial Phase 1 data from Gritstone-sponsored CORAL study expected early in the first Quarter 2022

https://pipelinereview.com/index.php/2021111079644/Vaccines/Gritstone-Announces-Positive-Preclinical-Data-in-Non-Human-Primate-Challenge-Study-with-Second-Generation-COVID-19-Vaccine-Against-SARS-CoV-2.html